Assessment of HES-CUR nanoparticles shows enhanced efficacy for ulcerative colitis via microbiota modulation and antioxidant pathway activation.
Key Points
HES-CUR nanoparticles significantly enhance microbiota diversity and improve colonic health in mice with ulcerative colitis.
TLR4/NF-κB pathway suppression and Nrf2 activation are key mechanisms behind the therapeutic effects of HES-CUR nanoparticles.
Microbiota analysis showed increased abundance of beneficial bacteria due to HES-CUR treatment, confirming its importance in colitis management.
HES-CUR nanoparticles demonstrated improved bioavailability and minimal toxicity, supporting their potential as safe natural therapies for ulcerative colitis.